12-1-2000

Technology evaluation: PRO-542, Progenics Pharmaceuticals inc.

Muhammad Mukhtar  
*Dorrance H Hamilton Laboratories, Department of Medicine, Jefferson Medical College, Philadelphia, PA 19107, United States,*  
Muhammad.Mukhtar@mail.tju.edu

Zahida Parveen  
*Dorrance H Hamilton Laboratories, Department of Medicine, Jefferson Medical College, Philadelphia, PA 19107, United States,*  
Zahida.Parveen@jefferson.edu

Roger J Pomerantz  
*Dorrance H Hamilton Laboratories, Department of Medicine, Jefferson Medical College, Philadelphia, PA 19107, United States,*  
Roger.J.Pomerantz@mail.tju.edu

Let us know how access to this document benefits you

Follow this and additional works at: [https://jdc.jefferson.edu/medfp](https://jdc.jefferson.edu/medfp)

Part of the [Medical Genetics Commons](https://jdc.jefferson.edu/medfp), and the [Medical Pharmacology Commons](https://jdc.jefferson.edu/medfp)

Recommended Citation

Mukhtar, Muhammad; Parveen, Zahida; and Pomerantz, Roger J, "Technology evaluation: PRO-542, Progenics Pharmaceuticals inc." (2000). Department of Medicine Faculty Papers. Paper 47.  
[https://jdc.jefferson.edu/medfp/47](https://jdc.jefferson.edu/medfp/47)

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University’s Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Medicine Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.
Technology evaluation: PRO-542, Progenics Pharmaceuticals Inc
Muhammad Mukhtar, Zahida Parveen & Roger J Pomerantz

Address
The Dorrance H Hamilton Laboratories
Department of Medicine
Jefferson Medical College
Thomas Jefferson University
Philadelphia
PA 19107
USA
Email: Muhammad.Mukhtar@mail.tju.edu

Current Opinion in Molecular Therapeutics (2000) 2(6):697-702
© PhamaPress Ltd ISSN 1464-8431

Progenics’s rCD4-IgG2 (PRO-542) is a recombinant fusion protein, which has been developed using the company’s Universal Antiviral Binding (UnAB) technology, and is in phase I/II clinical trials for the treatment of human immunodeficiency virus type I (HIV-1) infection [273391].

At the beginning of 1997, Progenics received a Phase II Small Business Innovation Research Program (SBIR) grant from the National Institute of Allergy and Infectious diseases (NIAID) to fund the development of PRO-542 [236048]. A further grant of $2.7 million was awarded in August 1998 for the clinical evaluation of PRO-542 and other anti-HIV therapies [294200].

Progenics is collaborating with the Aaron Diamond AIDS Research Center (ADARC) in New York and the Center for Disease Control and Prevention in Atlanta [178410]. In February 2000, Progenics and Genzyme Transgenics Corp signed an agreement to continue the development of a transgenic source of PRO-542. Genzyme will develop transgenic goats that produce PRO-542 in their milk in exchange for undisclosed fees and milestone payments. Genzyme will supply PRO-542 to Progenics for clinical trials with a possibility for eventual commercial supply [357291]. Following on from this, in October 2000, Progenics received an SBIR grant to fund a two-year project with Genzyme Transgenics into the development of cost-effective methods for the manufacture of PRO-542, by optimization of the production of the drug in the milk of transgenic dairy animals [385982].

In August 2000, Punk, Ziegel & Company predicted that Progenics Pharmaceuticals will become sustainably profitable in 2003 following the launch of PRO-542 and GMK (Progenics Pharmaceuticals) in 2002 [390063].

Introduction
PRO-542 is a universal antiviral-binding (UnAB)-based therapy. UnAB units are genetically engineered antiviral molecules that mimic permissive cell surface attachment regions. PRO-542 is a hybrid protein, incorporating the HIV-binding region of CD4, which is required by HIV to attach to host cells (T-cells) and initiate infection [383593]. PRO-542 acts as an attachment inhibitor, by binding to a viral surface glycoprotein, gp120, thus preventing HIV from attaching to the CD4 molecules on T-cells.

Since the discovery of HIV-1 interaction with CD4, several therapeutic strategies have been employed for the prevention and treatment of HIV-1 utilizing CD4-based therapeutics [383655], [383666]. A soluble form of CD4, termed sCD4, was developed as a 'molecular decoy' that binds to HIV-1 gp120 and inhibits viral attachment, as well as subsequent infection [383669]. In phase I clinical trials, sCD4 demonstrated a good safety profile; however, its antiviral effect was not well pronounced, probably due to a short half-life (45 min in humans following iv administration) [383679]. A dimeric CD4-human IgG1 heavy chain fusion protein has also been described [383634], which has a longer half-life, as well as in vitro antiviral activity [383636]. Development of this molecule was halted, however, due to potential drawbacks of Fc receptor-dependent complement activation [383634], [383637] and transfer of recombinant human CD4-IgG across the placenta [383677]. CD4-IgG2 conjugate (PRO-542) was developed to overcome the potential problems associated with half-life and Fc receptor-mediated complement activation. It has a longer half-life and does not interact with the high-affinity Fc receptors on human monocytic U937 cells [383593].

PRO-542 has been developed for use in two clinical settings: (i) post-exposure prophylaxis and (ii) immunotherapy. In post-exposure prophylaxis therapy, PRO-542 would protect exposed individuals from contracting HIV infection by reducing the concentration of infectious virus in the bloodstream. As an immunotherapy, PRO-542 could be used to treat HIV infection, especially during the early or asymptomatic phase of infection [178410], [278442].

Synthesis and SAR
PRO-542 is a fusion protein comprising human IgG2 in which the Fv portions of both heavy and light chains have been replaced with four copies of the D1 and D2 domains of human CD4 [341870], [383593], [383659]. PRO-542 has been expressed in Chinese hamster ovary (CHO) cells, where it is secreted as a fully assembled heterotetramer, and purified using size-exclusion chromatography. Its tertiary structure was determined based on its high binding affinity for recombinant soluble gp120 from both laboratory-adapted and primary isolates of HIV-1 [383593].

PRO-542 was designed to bind multiple copies of gp120, and appears to be able to neutralize HIV by crosslinking up to four gp120s on the surface of one or more virus particles.
Electron microscopy has been used to visualize PRO-542 alone and complexed with gp120 viral envelope glycoprotein that protrudes from the virus. These studies confirmed the structural flexibility of PRO-542 and its complexation with four molecules of gp120 [36535]. PRO-542 acts by two mechanisms: (i) by high-affinity binding to gp120; and (ii) by detaching gp120 from the HIV particle, thereby inactivating the virus [178410].

In order to produce sufficient quantities of the antibody-like molecule in a cost effective manner, Progenics Pharmaceuticals initiated a program in 1998 with Genzyme Transgenics Corp to develop a means of expressing PRO-542 in the milk of transgenic animals [278442], [279692].

**Pharmacology**

PRO-542 has been developed as an immunoprophylactic agent for reducing the probability of infection after HIV-1 exposure [383593], [383650]. Binding of PRO-542 to glycoprotein gp120 is the basis of HIV-1 neutralization. It has been observed that PRO-542 binds at nanomolar concentrations to purified gp120 isolated from both primary and laboratory-adapted HIV-1 isolates [383593]. In rabbits, PRO-542 has a terminal half-life of 26.4 h, compared to mean terminal serum half-lives in humans of 4.2 ± 0.9 and 3.3 ± 0.7 days for 5 and 10 mg/kg doses, respectively [383593], [383659].

On the basis of flow cytometric analysis, PRO-542 does not appear to bind to Fc receptors, a property that is desirable since an agent with Fc-binding capability will be lethal for uninfected cells bearing this surface receptor. PRO-542 inhibits syncytia formation in HIV-1-infected cells, suggesting that it would successfully prevent cell-to-cell HIV-1 transmission [383593]. Furthermore, it was effective against diverse laboratory-adapted and primary HIV-1 isolates, including strains with different tropisms and isolated at different stages of disease [383650], [383652]. In a hu-PBL-SCID mouse model, passive administration of PRO-542 10 mg/kg, protected animals against subsequent infectious doses of laboratory-adapted T-cell-tropic isolate HIV-1 (LAI), while a 50 mg/kg dose protected four out of five mice against the primary isolates HIV-1 (JR-CSF) and HIV-1 (AD6) [383652].

The synergistic inhibition of HIV-1 using combinations of PRO-542 and other antiviral agents has also been investigated [374349], [378084], [380352], [381776], [382628]. A combination of PRO-542 and T-20 (pentafuside; Duke University/Trimeris Inc) was especially potent in blocking HIV entry into cells. T-20 is derived from gp41. The activity of each agent, both of which are termed ‘entry inhibitors’, was greatly enhanced by the presence of the other, resulting in synergistic or supra-additive antiviral effects. In *in vitro* studies, PRO-542 and T-20 synergistically blocked both virus-to-cell and cell-to-cell spread of HIV; the levels of each agent required to achieve biologically relevant inhibition were reduced by approximately 10-fold [374349], [381776].

PRO-542 was also tested in combination with T-20 and PRO-140 (Progenics Pharmaceuticals), each of which inhibits a different step in the sequence of events leading to the entry of HIV into target cells. PRO-140 is a monoclonal antibody to CCR5, which potently blocks HIV-1 entry but not CC-chemokine signaling through CCR5. Potent synergies were observed for certain combinations of these HIV-1 inhibitors. In such instances, the drug levels required to achieve clinically relevant levels of inhibition were reduced 5- to 15-fold and no agent antagonized the activity of another [378084], [380352], [382628].

**Metabolism**

In a phase I clinical trial in which PRO-542 0.2 to 10 mg/kg was administered iv to HIV-infected adults, the area under the concentration-time curve and peak serum concentrations increased linearly with dose, and the terminal serum half-life was 3 to 4 days [383659].

**Toxicity**

One of the potential concerns for recombinant fusion protein therapeutics is unintentional product reactivity. Phase I trial data in HIV-infected adults supported the non-immunogenic nature of PRO-542 [341870]. In this study, the drug was well tolerated and no dose-limiting toxicities were identified [341870], [383659].

**Clinical Development**

**Phase I/II**

A single-dose phase I/II study was conducted at the Mount Sinai Medical Center, NY, USA, evaluating the safety, pharmacology and antiviral activity of PRO-542 in HIV-1 infected adults (with criteria of viral load ≥ 3000 copies/ml of viral RNA, CD4 counts > 50 cells/mm² and stable or not receiving anti-HIV therapy) [341870], [375598], [383659]. In this study, individuals were treated with one of four doses of PRO-542 (0.2, 1.0, 5.0 or 10.0 mg/kg body weight). Patients in the high-dose group reached a serum concentration of > 500 µg/ml and experienced a statistically significant reduction in plasma HIV RNA; the reductions in infectious HIV plasma levels were sustained [341870], [341337], [375598], [383659].

A second multicenter phase I/II study was carried out in pediatric patients at Baylor College of Medicine in Houston, TX, the University of California at San Francisco, CA and the University of Pennsylvania, PA, by the AIDS Clinical Trials Group (ACTG) [284326], [354249]. In one of these multi-dose trials, 18 HIV-1-infected children were treated with a single infusion or 4 weekly doses of PRO-542. The six children treated weekly with PRO-542 all demonstrated a decrease in HIV RNA of up to 1.5 log₁₀. Three of the children showed sustained reductions in viral loads that persisted for as long as 14 days post-treatment [354249], [374349]. No serious drug-related adverse events were observed.

PRO-542 has now completed these two phase I/II clinical trials [383541].

**Side Effects and Contraindications**

Single-dose iv administration of 0.2 to 10 mg/kg of PRO-542 was well tolerated and no significant drug-related adverse events were reported [341870]. No patients developed antibodies to PRO-542 [383659]. PRO-542 was also well tolerated in pediatric clinical trials [374349].
Current Opinion

AIDS and HIV infection represent one of the most serious health threats facing mankind. Currently, highly active antiretroviral therapy (HAART) is considered the most promising therapeutic option, although a number of studies document residual virus in HAART patients [383681]. UnAB technology, and specifically PRO-542 with its novel mode of action [383657], represents an interesting approach to the treatment of HIV and AIDS. Monotherapy with PRO-542 in phase I/II clinical trials in HIV-infected adults and children, demonstrated good safety, tolerability, pharmacokinetics and reduction of HIV RNA levels [284326], [341870], [374349], [375598], [383659]. With the recent completion of phase I/II clinical trials, and the fact that Progenic Pharmaceuticals are collaborating with Genzyme Transgenics for the development of a transgenic source of PRO-542 (goats milk), with a possibility for eventual commercial supply [357291], indicates that the company are continuing the clinical development of this therapy.

A serious challenge to PRO-542, however, is CD4-independent infection, which suggests that gp120 interaction with CD4 surface molecules is not necessary for infection in certain cell types [383671]. In addition, it is also important to consider previous studies that show that the virus envelope proteins are not required for virus attachment [383675].

In vitro studies of combination therapies, ie, PRO-542 + T-20 and PRO-542 + T-20 + PRO-140, show that these double- and triple-drug cocktails act synergistically and potently [374349], [378084], [380352], [381776], [382628]. The key to these combination therapies is that each individual drug acts at a different step in the sequence of events leading to HIV entry/infection of host cells [382628]. It will be interesting to see how the PRO-542-combination therapies compare with traditional HAART programs currently under investigation and in use.

Licensing

Aaron Diamond AIDS Research Center

Progenics Pharmaceuticals Inc and Aaron Diamond AIDS Research Center are collaborating on the development of PRO-542 [178410].

American Cyanamid Co

American Cyanamid and Progenics agreed to collaborate on the study of several agents combining the use of Progenics HIV Universal Neutralizing Antibody technology (UnAB) with drug conjugates [167582].

Genzyme Transgenics Corp

Progenics and Genzyme Transgenics have signed an agreement to continue the development of a transgenic source of supply for PRO-542. Genzyme will develop transgenic goats that produce PRO-542 in their milk in exchange for undisclosed fees and milestone payments [357291].

Development History

<table>
<thead>
<tr>
<th>Developer</th>
<th>Country</th>
<th>Status</th>
<th>Indication</th>
<th>Date</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aaron Diamond AIDS Research Center</td>
<td>US</td>
<td>C2</td>
<td>AIDS</td>
<td>06-JAN-98</td>
<td>273391</td>
</tr>
<tr>
<td>Progenics Pharmaceuticals</td>
<td>US</td>
<td>C2</td>
<td>AIDS</td>
<td>06-JAN-98</td>
<td>273391</td>
</tr>
</tbody>
</table>

Literature classifications

Key references relating to the technology are classified according to a set of standard headings to provide a quick guide to the bibliography. These headings are as follows:

**Biology**: References which discuss synthesis and structure-activity relationships.

**Clinical**: Reports of clinical phase studies in volunteers providing, where available, data on the following: whether the experiment is placebo-controlled or double- or single-blind; number of patients; dosage.

**Biology**

<table>
<thead>
<tr>
<th>Study Type</th>
<th>Effect Studied</th>
<th>Experimental Model</th>
<th>Result</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>In vivo</td>
<td>Neutralization of primary HIV-1 isolates.</td>
<td>hu-PBL-SCID mice.</td>
<td>PRO-542 10 mg/kg protects all animals against challenge with laboratory-adapted T-cell-tropic isolate HIV-1 (LAI), while 50 mg/kg protected 4/5 mice against the primary isolates HIV-1 (JR-CSF) and HIV-1 (AD6).</td>
<td>383652</td>
</tr>
</tbody>
</table>

| In vitro   | gp120 Binding affinity.                      | Laboratory-adapted strain and a primary isolate of HIV-1. | PRO-542 has nanomolar binding affinity.                                | 383593    |
### Biology (continued)

<table>
<thead>
<tr>
<th>Study Type</th>
<th>Effect Studied</th>
<th>Experimental Model</th>
<th>Result</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>In vitro</td>
<td>Inhibition of syncitium formation.</td>
<td>Virus-free HIV-1 envelope glycoprotein.</td>
<td>Tetrameric CD4-IgG2 (PRO-542) inhibited syncitium formation more effectively than monomeric sCD4 or dimeric CD4-γ 2 fusion protein.</td>
<td>383593</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Tetrameric CD4-IgG2 (PRO-542) inhibition was better than monomeric sCD4 or dimeric CD4-γ 2 fusion protein.</td>
<td></td>
</tr>
<tr>
<td>In vivo</td>
<td>Pharmacokinetics.</td>
<td>Rabbit.</td>
<td>Plasma terminal t½ = 26.4 h.</td>
<td>383593</td>
</tr>
<tr>
<td>In vitro</td>
<td>Synergistic inhibition by PRO-542 + T-20</td>
<td>Preclinical models of HIV-1 infection.</td>
<td>Good synergy observed for certain combinations. Drug levels required for clinically relevant inhibition reduced by 10-fold.</td>
<td>378084</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Good synergy observed for certain combinations. Drug levels required for clinically relevant inhibition reduced by 5- to 15-fold.</td>
<td>380352</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Good synergy observed for certain combinations. Drug levels required for clinically relevant inhibition reduced by 10-fold.</td>
<td>382628</td>
</tr>
</tbody>
</table>

### Clinical

<table>
<thead>
<tr>
<th>Study Type</th>
<th>Effect Studied</th>
<th>Result</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase I/II.</td>
<td>Single-dose safety, pharmacology and antiviral activity in HIV-1-infected adults.</td>
<td>PRO-542 0.2 to 10 mg/kg iv was well tolerated, no dose-limiting toxicity observed, terminal t½ = 3 to 4 days. Evidence of antiviral activity observed as reductions in plasma HIV RNA and plasma viremia.</td>
<td>341337</td>
</tr>
<tr>
<td>Phase I/II.</td>
<td>18 HIV-1-infected children, treated with a single infusion or 4 weekly doses of PRO-542.</td>
<td>All six children receiving weekly doses showed decreased plasma HIV-1 RNA (up to 1.5 log₁₀). Three of the children showed sustained reductions in viral load that persisted for as long as 14 days post-treatment. No serious drug-related adverse events were reported.</td>
<td>354249</td>
</tr>
</tbody>
</table>

### Associated Patent

**Title** Compounds capable of inhibiting HIV-1 infection.

**Assignee** Progenics Pharmaceuticals Inc

**Publication** WO-9726099 24-JUL-97


**Inventors** Madden PJ, Allaway GP, Liwin V

### References

- of special interest
- 278442. Genzyme Transgenics Corp: Progenics and Genzyme Transgenics announce initiation of program to produce novel HIV therapeutics. Press release 18 February (1998). - Announcement of an agreement between Genzyme Transgenics Corp and Progenics Pharmaceuticals of a program to produce PRO-542 in the milk of transgenic animals. Following successful completion of the initial development phase, the companies expect to enter into a commercialization agreement for production of PRO-542 in the milk of transgenic goats.
- Initial results of a phase I/II trial in 15 HIV-infected patients who received a single injection of PRO-542.


- Initial results from a pediatric phase I/II clinical trial of PRO-542.


- Electron microscopy studies demonstrate that PRO-542 possesses exceptional structural flexibility and may be able to neutralize HIV by crosslinking as many as four gp120s on the surface of one or more virus particles.


- Report that phase I/II clinical trials of PRO-542 have been completed.


- Publication of the results of phase I/II clinical trials of PRO-542 in HIV-infected patients.


